Flagship and the Cystic Fibrosis Foundation team up on a novel research pact to chase down potential cures
Amid Moderna’s quick rise to the top, the investor behind the firm, Flagship Pioneering, has never been more prominent or unshakeably confident. Now, looking to crack the code on a cure for cystic fibrosis, the uber-incubator is partnering up with a leading nonprofit to chase the impossible.
Flagship’s Pioneering Medicines unit and the Cystic Fibrosis Foundation will team up on a novel industry-nonprofit collaboration to pursue therapeutic breakthroughs in the crippling lung disease, with the nonprofit ponying up $110 million in R&D funding for a planned newco, the partners said Wednesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.